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ABSTRACT
Background & Aims
In patients with chronic hepatitis C who failed to respond to standard therapy, high-dose pegylated interferon (IFN)-α and/or ribavirin could induce a stronger antiviral response and prevent treatment failure and HCV resistance when combined with direct acting antivirals. The influence of genetic determinants in this context remains unknown.
Methods
Eighty-three patients infected with HCV genotype 1 who were non-responsive to standard therapy received pegylated IFN-α2a (360 µg once per week or 180 µg twice per week) with ribavirin (1.0-1.2 or 1.2-1.6 g/day) for up to 72 weeks. Virological responses were assessed at different time points, and the influence of the IL28B genotype was studied.
Results
At weeks 12 and 24 respectively, 47 (56.6%) and 50 (60.2%) patients achieved a 2-Log 10 or more decrease of HCV RNA levels; 8 (9.6%) and 21 (25.3%) patients had undetectable HCV RNA after 12 and 24 weeks of treatment, respectively. Patients with a CT IL28B genotype responded significantly better and earlier than those with a TT genotype. In multivariate analysis, the IL-28B genotype was an independent predictor of the virological responses at weeks 4, 12 and 24.
Conclusions
High-dose pegylated IFN-α, with standard or high doses of ribavirin, induces a potent antiviral response in a substantial number of patients who did not respond to standard therapy. The IL28B genotype is an independent predictor of the antiviral 4 response. High-dose pegylated IFN-α in combination with ribavirin and protease inhibitors appears as an attractive option for future study in this population.
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INTRODUCTION
Hepatitis C virus (HCV) chronically infects approximately 120-130 million individuals worldwide. 1 Chronic HCV infection is a major cause of life-threatening liver disease, and approximately 20% of HCV-infected patients develop cirrhosis. 2 Indeed, HCV infection is the main indication for liver transplantation, and is becoming the leading cause of hepatocellular carcinoma in industrialized areas. 2 Mortality related to HCV infection has been estimated at approximately 300,000 deaths per year.
HCV infection is curable by therapy. Current treatment is based on a combination of pegylated interferon (IFN)-α and ribavirin. In patients infected with
HCV genotype 1, by far the most frequent HCV genotype worldwide, only 40% to 50% of such treatment lead to a cure of infection. [3] [4] [5] Failure of IFN-α-based treatments to eradicate HCV infection has been recently shown, at least partly, to be genetically determined. Single nucleotide polymorphisms (SNPs) in the region upstream of the IL28B (IFN-λ3) gene in chromosome 19 have been identified to be strongly associated with the ability of pegylated IFN-α and ribavirin to cure HCV infection. [6] [7] [8] The underlying mechanisms remain obscure.
In 2011, new treatments will be available for chronic HCV genotype 1 infection. They will be based on a combination of pegylated IFN-α, ribavirin and a specific HCV protease inhibitor, telaprevir or boceprevir. Phase II and III clinical trials have shown that approximately 25%-35% of treatment-naïve patients, and 50%-60%
of those who have previously failed on pegylated IFN-α and ribavirin alone, fail to 6 eradicate HCV on such triple combination. 9, 10 11-17 Treatment failure is principally due to an insufficient antiviral response to pegylated IFN-α and ribavirin, favoring the growth of protease inhibitor resistant viruses selected by the direct acting antiviral agent. 10, 12, 13, 18 Therefore, a sufficient antiviral response to pegylated IFN-α and ribavirin is an absolute prerequisite in order to achieve cure of infection with new triple combination therapies without selecting for resistant viruses.
As recent reports indicated that the outcome of triple combinations with pegylated IFN-α, ribavirin and an HCV protease inhibitor strongly depends on the ability of IFN-α and ribavirin to substantially reduce HCV replication, 10, 12, 13, 18 which has recently been shown to be strongly associated with IL28B polymorphisms, 6-8, 19, 20 we decided to assess the ability of high doses of pegylated IFN-α with standard or high doses of ribavirin to induce a significant antiviral response in genotype 1 patients who failed to respond to a first course of therapy at standard doses and whether responsiveness to high-dose pegylated IFN-α and ribavirin is genetically driven in this population.
PATIENTS AND METHODS
Patients
The Mondor, Créteil, France).
All of the analyses have been performed on the intent-to-treat population, which included 98 non-responder patients who received at least one dose of study drug and had at least one HCV RNA measurement under treatment. After the report of a relationship between IL28B genotype and the response to IFN-α-based therapy,
another amendment was passed in order to allow us to test the patients for IL28B
genotype. Eighty-three of the 98 patients gave their informed consent to the genetic testing and constitute the study population of this article. The baseline characteristics of the patients who did not give their informed consent did not differ from those in the study patients. As no significant differences in virological response rates were observed between the treatment groups at different time points, the patients from the 4 groups were considered together in this study.
HCV RNA level monitoring
HCV RNA levels were measured at baseline and at weeks 1, 2, 4, 12, 24, 48
and 72 of therapy. In the patients receiving 72 weeks of therapy, HCV RNA levels were also measured at week 96, i.e. 24 weeks after the end of treatment. The COBAS AmpliPrep ® /COBAS TaqMan ® automated real-time PCR platform (Roche Molecular Systems, Pleasanton, California). This assay has a lower limit of detection of 15 IU/mL and a lower limit of quantification of 43 IU/mL. 21 The sustained virological response (SVR) was defined as an undetectable HCV RNA 24 weeks after the end of therapy; the SVR corresponds to a cure of infection in more than 99% of cases. 
Statistical analysis
Statistical analysis was performed with SAS 9.1 software (SAS Institute Inc., Cary, North Carolina). Tests were two-sided and a type I error was set at 0.05.
Missing data were not replaced. The week 1 virological response was calculated between treatment start and day 7 of therapy. The second-phase slope was computed by linear regression using HCV RNA levels at days 8 and 28 of therapy.
Comparisons between IL28B genotypes (CT versus TT) were performed using Chi- 
Role of the funding source
This study is investigator-initiated. It has been sponsored by Roche (Neuillysur-Seine, France). Roche also provided medication and support for statistical analysis. Table 1 shows the characteristics of the 83 patients who gave their consent for the IL28B analysis. All of them had undergone a first course of therapy with standard doses of pegylated IFN-α2a and ribavin, had received more than 80% of the pegylated IFN-α2a and ribavin dose, and had stopped therapy at week 12 because they failed to achieve a more than 2 Log 10 HCV RNA level drop. They were retreated with high-dose pegylated IFN-α combined with standard-or high-dose ribavirin. No significant differences (and no trend toward differences) in virological responses were observed between the 4 treatment groups (either 360 µg once per week or 180 µg twice per week of pegylated IFN-α, combined with a standard or a high dose of ribavirin) at different time points. In particular, there was no influence of a standard or a high dose of ribavirin on virological outcomes (data not shown). Thus, the patients from the 4 groups were pooled together for analysis in order to assess the virological response to retreatment with a high dose of pegylated IFN-α (with a standard or high dose of ribavirin) and the influence of the IL28B genotype on this response. Figure 1 shows a flow chart of patient disposition in the trial. The following results are based on intent-to-treat analysis.
RESULTS
Characteristics of the study patients
Only 3 patients had a CC genotype at IL28B SNP position rs12979860. Their characteristics at baseline did not differ from those in the remaining patients. Two of them did not achieve a 2-Log 10 HCV RNA decline and stopped therapy at week 24 as per the protocol stopping rule; the third one responded but failed to achieve an SVR. The CC patients were thus removed from the analysis to allow for comparison of the 55 (66.3%) CT and the 25 (30.1%) TT patients. The characteristics of the patients did not differ between these two groups. In particular, there was no significant difference in the mean HCV RNA levels at baseline (p=0.76) ( Table 1) .
Virological response to high-dose pegylated IFN-α with ribavirin
At week 12, 48 of the 83 patients (57.8%) who had not responded to a standard treatment dose (less than 2-Log 10 HCV RNA level drop) achieved a 2-Log 10 or more HCV RNA level drop and 8 (9.6%) had undetectable HCV RNA (<15 IU/mL). Table 2 , patients with a CT genotype responded significantly better (and earlier) to high-dose pegylated IFN-α and ribavirin than those with a TT genotype. Indeed, the proportions of CT patients with a more than 0.5, 1.0, or 2.0 Log 10 HCV RNA decrease were significantly higher than those in TT patients at weeks 2, 4, and 12-24, respectively. At weeks 24, 48 and at week 72 (end of treatment in patients who had undetectable HCV RNA at week 48), the proportion of patients with an undetectable HCV RNA was significantly higher in the CT patients than in the TT patients. The 5 patients who achieved an SVR were all in the CT group (9.1% vs 0%, not significant).
As shown in Figure 2 , the average HCV RNA decline during the first 7 days of therapy, that combines both first-and second-phase HCV RNA declines, was slightly but not significantly greater in CT than in TT patients (-0.35±0.49 vs -0.24±0.34 Log 10 IU/mL, respectively; p=0.33). In contrast, the average weekly HCV RNA decline between days 8 and 28 of therapy, which accurately measures the second-phase decline, was significantly greater in CT than in TT patients (-0.28±0.17 vs -0.18±0.12
Log 10 IU/mL/week, respectively; p=0.004).
Predictors of virological responses to high-dose pegylated IFN-α and ribavirin
As shown in Table 3 , the IL-28B genotype was an independent predictor of the virological response at all tested time points, with CT patients being significantly more likely to respond than TT patients. Other predictors of response included female gender, body mass index (paradoxically, bigger patients responded better to high-dose therapy), the absence of cirrhosis, a more than 0.5 Log 10 HCV RNA decrease during the first course of therapy with standard doses of pegylated IFN-α and ribavirin, and a low HCV RNA level at baseline (Table 3) . 
Predictive value of the IL28B genotype on virological responses to highdose pegylated IFN-α and ribavirin
Adverse events
Every patient experienced at least one adverse event during the study period;
23 of them (27.7%) experienced at least one severe adverse event. Treatment discontinuation due to an adverse event or to a severe adverse event has been observed in 11 (13.3%) and 6 (7.2%) cases, respectively. Table 5 shows the most frequent (≥10%) adverse events observed in the 83 patients during the trial. In contrast with a recent observation in patients receiving a standard dose of pegylated IFN-α and ribavirin, 23 no significant difference was observed between CT and TT patients (data not shown).
DISCUSSION
In this study, patients chronically infected with HCV genotype 1 who failed to respond to a standard dose of pegylated IFN-α and ribavirin by a more than 2-Log 10 HCV RNA level drop were retreated with a high dose of pegylated IFN-α2a and a standard or high dose of ribavirin. High-dose pegylated IFN-α2a was administered for the full duration of therapy, which was extended to 72 weeks if HCV RNA was undetectable at week 48. In this respect, the design of the trial was original, as formerly published retreatment trials used either standard doses of pegylated IFN-α and ribavirin for the full treatment course or short-term induction with high-dose pegylated IFN-α at the beginning of therapy. [24] [25] [26] [27] These studies generally also included patients who responded by a more than 2-Log 10 HCV RNA level drop at week 12 but subsequently failed to achieve an SVR during the first course of therapy.
In spite of these differences, only 5 patients in this trial (6%) achieved an SVR, all of them belonging to the CT group.
An important finding in this study was that, in patients who were not able to A recent study assessing frequent viral kinetics in treatment-naïve patients receiving standard doses of pegylated IFN-α and ribavirin has shown nearly identical early viral kinetics among CT and TT patients. 28 CC patients, who achieve the highest rates of viral clearance, had a significantly steeper first-phase HCV RNA level decline than both CT and TT patients, while their second-phase slopes were not different. 28 This suggested that the IL28B genotype essentially influences the ability of the patients to mount a potent direct antiviral response against HCV in response to IFN-α. Our data suggest that, when higher doses of pegylated IFN-α are used, CT patients respond significantly better than TT patients. In addition, the maximum effect of the IL28B genotype in our study was on the second-phase decline, which measures the progressive clearance of infected cells. High doses of pegylated IFN-α could trigger antiviral mechanisms that are not involved when standard doses are used, and/or the lower level of "resistance" of cells from CT patients to the action of IFN could allow them to respond when exposure is increased.
Our sampling schedule did not allow us to study the first-phase decline in our patients. We cannot rule out a role for a difference between CT and TT patients in the first-phase decline that would ultimately influence the second-phase decline.
Indeed, in patients who are naturally poorly responsive to IFN-α and ribavirin, a modest reduction of HCV RNA levels below a threshold that triggers infected cell clearance (or cure ?) could have visible consequences on the second-phase decline only. These hypotheses will be difficult to verify unless appropriate experimental models are available and the molecular mechanisms underlying the relationship between IL28B polymorphisms and HCV response to IFN-α-based therapy are unraveled.
Overall, our data suggest that high-dose pegylated IFN-α, in combination with a standard or a high dose of ribavirin, is an interesting option for combination with telaprevir or boceprevir in order to minimize the risk of resistance selection and increase the SVR rates in non-responders to prior standard therapy. This is reinforced by the fact that these treatments would be given for 24 to 48 weeks, and the antiviral effect was sustained over this duration in our study in patients who responded. The minimal antiviral effect of pegylated IFN-α and ribavirin to achieve a high cure rate is still unknown. Phase II and III trials with pegylated IFN-α2b, ribavirin and boceprevir, which included a lead-in phase with pegylated IFN-α2b and ribavirin alone, suggested that it could be of the order of 1.0-1.5 Log 10 IU/mL at week 4. 10, 15, 16 Results from the REALIZE trial with pegylated IFN-α2a, ribavirin and telaprevir, which included a lead-in phase with pegylated IFN-α2a and ribavirin alone, are awaited.
Although the IL28B genotype is a strong, independent predictor of the ability of high-dose pegylated IFN-α and ribavirin to induce an antiviral response in nonresponders, the individual predictive value of this marker was not very high in our study. Specifically, a substantial number of TT patients were able to achieve a significant antiviral response on treatment. Therefore IL28B genotyping should not be recommended as a tool to deny high-dose pegylated IFN-α and ribavirin therapy in non-responders retreated with a triple combination. Nevertheless, non-responder CT patients represent an ideal population for this strategy. Stratification on the IL28B genotype should therefore be recommended in future trials assessing strategies based on high-dose pegylated IFN-α and ribavirin.
Other predictors of response at different time points included a female gender, the absence of cirrhosis, a more than 0.5 Log 10 HCV RNA decline during the first course of therapy at standard doses and a low baseline HCV RNA level, parameters known to be associated with better SVR rates in HCV-infected patients. [3] [4] [5] . The noted effects of increased BMI appeared paradoxical, as bigger patients had a better response at weeks 12 and 24. This could be explained by the fact that higher doses work particularly well in patients in whom the principal cause of failure was a high BMI, responsible for insufficient IFN-α exposure during the first treatment course.
In conclusion, this study shows that high-dose pegylated IFN-α, with standard or high doses of ribavirin, is able to induce a potent antiviral response in a substantial number of patients who did not respond or responded poorly to a standard dose 
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